



CAPLIN POINT
LABORATORIES LTD.

CIN : L24231TN1990PLC019053

Regd. Off. : "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone : +91 44 28156653, 28156905
Fax : +91 44 28154952 E-mail : info@caplinpoint.net Website : www.caplinpoint.net

05.02.2016

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building.
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

By Listing Centre

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051.
Scrip Code: CAPLIPOINT

By NEAPS

Dear Sirs,


Sub: Un-audited Financial Results for the quarter /Half year ended December 31,2015.

Herewith we enclose the un-audited Financial Results for the quarter/Half year ended December 31,2015 along with the Limited review report.

Kindly take the same on your records.

Thanking You,

Yours Truly,
For Caplin Point Laboratories Limited


Company Secretary
Enclosures: As above.

CAPLIN POINT LABORATORIES LIMITED
Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017
CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31st DECEMBER 2015

Part I Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited Year ended June 30, 2015
	Three months ended					
	Dec 31, 2015	Sept 30, 2015	Dec 31, 2014	Dec 31, 2015	Dec 31, 2014	
	Rs. In Lakhs					
1 Income						
a. Net Sales/ income from operations (Net of Excise Duty)	7,552.02	7,432.79	5,518.29	14,984.81	10,800.32	23,135.87
b. Foreign Exchange Fluctuation Gain	-	-	-	-	-	-
c. Share of profits in LLP	164.26	116.03	227.84	280.29	375.40	886.93
d. Total	7,716.28	7,548.82	5,746.13	15,265.10	11,175.72	24,022.80
2 Expenditure						
a. Cost of materials consumed	1,000.56	1,058.02	983.99	2,058.58	1,644.41	3,573.57
b. Purchase of Stock-in-Trade	2,614.95	2,797.05	2,056.44	5,412.00	4,547.40	9,375.13
c. Change in inventories of Finished Goods, work in progress and stock in trade	164.76	136.38	91.42	301.14	42.57	(124.22)
d. Employees benefit expenses	581.01	533.91	442.65	1,114.92	839.27	1,838.14
e. Depreciation	264.14	209.80	188.59	473.94	383.08	827.92
f. Foreign Exchange Fluctuation Loss	196.43	89.86	138.57	286.29	130.01	278.65
g. Research and Development Expenses	202.46	137.91	135.01	340.37	257.83	588.24
h. Other Expenditure	746.21	740.68	665.17	1,486.89	1,343.73	2,837.20
i. Total	5,770.52	5,703.61	4,701.84	11,474.13	9,188.30	19,194.63
3 Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)	1,945.76	1,845.21	1,044.29	3,790.97	1,987.42	4,828.17
4 Other Income	115.23	79.05	73.38	194.28	127.82	274.40
5 Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)	2,060.99	1,924.26	1,117.67	3,985.25	2,115.24	5,102.57
6 Finance cost	4.93	2.99	4.54	7.92	9.29	22.79
7 Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional items (5-6)	2,056.06	1,921.27	1,113.13	3,977.33	2,105.95	5,079.78
8 Exceptional items	-	-	-	-	-	-
9 Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)	2,056.06	1,921.27	1,113.13	3,977.33	2,105.95	5,079.78
10 Provision for Taxation	457.59	446.07	172.00	903.66	362.00	950.74
Provision for Taxation - earlier years	-	-	-	-	(80.00)	(80.00)
Deferred Tax Provision	0.85	55.36	30.00	56.21	60.00	115.48
Mat Credit Entitlement	-	-	-	-	-	-
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	1,597.62	1,419.84	911.13	3,017.46	1,763.95	4,093.56
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13 Net Profit(+)/Loss(-) for the period (11-12)	1,597.62	1,419.84	911.13	3,017.46	1,763.95	4,093.56
14 Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
15 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	7,479.02
16 Earnings/(Loss) Per Share (EPS) (Not annualised)						
(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	10.57	9.40	6.03	19.97	11.67	27.09
(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	10.57	9.40	6.03	19.97	11.67	27.09

Part II		Select information for the Quarter ended 31st DECEMBER 2015					
		Three months ended			Six months ended		Year ended
		Unaudited	Unaudited	Unaudited	Unaudited		Audited
		Dec 31, 2015	Sept 30, 2015	Dec 31, 2014	Dec 31,		June 30, 2015
		2015	2015	2014	2014	2015	
A	PARTICULARS OF SHARE HOLDING						
17	Public Shareholding						
	- Number of Shares	48,63,247	48,63,247	62,39,247	48,63,247	62,39,247	48,63,247
	- Percentage of Shareholding	32.19%	32.19%	41.29%	32.19%	41.29%	32.19%
18	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	102,46,753	102,46,753	88,70,753	102,46,753	88,70,753	102,46,753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	67.81%	67.81%	58.71%	67.81%	58.71%	67.81%
B	Particulars	3 months ended 31-12-2015					
	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	Nil					
	Received during the quarter	172					
	Disposed of during the quarter	171					
	Remaining unresolved at the end of the quarter	1					

STATEMENT OF ASSETS AND LIABILITIES	UNAUDITED STANDALONE-STATEMENT OF ASSETS AND LIABILITIES FOR THE HALF-YEAR ENDED 31ST DEC 2015		
	Unaudited Six Months ended		Audited Year ended
	31-12-2015	31-12-2014	30-06-2015
Particulars	Rs. in Lakhs	Rs. in Lakhs	Rs. in Lakhs
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	1,511.00	1,511.00	1,511.00
Reserves and surplus	10,924.27	6,480.98	7,852.40
Total Shareholders' Funds	12,435.27	7,991.98	9,363.40
Minority Interest			
Non current liabilities			
Long-term borrowings	57.46	154.04	87.99
Deferred tax liabilities (Net)	925.56	813.87	869.35
Long-term provisions	106.04	96.74	82.04
Total Non Current Liabilities	1,089.06	1,064.65	1,039.38
Current Liabilities			
Short-term borrowings	-	5.00	5.00
Trade Payables	4,060.34	2,779.14	3,817.27
Other current liabilities	6,759.44	8,824.65	7,135.74
Short-term provisions	337.78	531.45	960.13
Total Current Liabilities	11,157.56	12,140.24	11,918.14
TOTAL	24,681.88	21,196.87	22,320.92
ASSETS			
Non Current Assets			
Fixed assets			
(i) Tangible Assets	13,948.31	10,172.79	11,087.94
(ii) Intangible Assets	-	56.37	59.46
(iii) Capital work-in-progress	93.68	3,527.64	3,025.61
(iv) Intangible Assets under Development	35.59	9.01	36.94
Non-current investments	143.10	54.86	144.01
Long-term loans and advances	174.38	538.50	257.12
Total Non Current Assets	14,395.06	14,359.17	14,611.08
Current Assets			
Inventories	1,091.07	942.98	1,265.89
Trade receivables	130.80	1.90	1.65
Cash and cash equivalents	6,138.35	3,868.24	4,031.93
Short-term loans and advances	2,788.65	1,954.97	2,290.40
Other current assets	137.95	69.61	119.97
Total Current Assets	10,286.83	6,837.70	7,709.84
TOTAL	24,681.88	21,196.87	22,320.92

Notes :

- The Company operates in one segment only.
- The above consolidated unaudited financial results were considered and recommended by the Audit Committee of the Board and have been approved by the Board of Directors at its meeting held on 05.02.2016
- The statutory auditors have carried out a limited review of the results for the quarter and half year ended 31st December 2015
- The Board at its Meeting held on 5th February, 2016 declared an interim Dividend of Rs. 2.50 per share (25%) for the year 2015-16 and the same will be paid to those shareholders who hold shares in physical form and / or in electronic form and whose names appear in the Register of Members and / or Depositories respectively as at the closing hours on 16th February, 2016 (Record Date).
- The consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the company.
- Prior year / period figures are regrouped / rearranged wherever necessary.



Dr. Sridhar Ganesan
Managing Director

Place : Chennai
Dated : 05.02.2016

CAPLIN POINT LABORATORIES LIMITED
Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017
CIN - L24231TN1990PLC019953, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31st DECEMBER 2015

Part I	Particulars	Three months ended			Six months ended		Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		Dec 31,	Sept 30,	Dec 31,	Dec 31,	Dec 31,	June 30,
		2015	2015	2014	2015	2014	2015
	Rs. in Lakhs					Rs in Lakhs	
1	Income						
	a. Net Sales/ income from operations (Net of Excise Duty)	7,926.94	7,754.27	6,088.31	15,681.21	11,802.32	25,176.98
	b. Foreign Exchange Fluctuation Gain	-	-	-	-	-	-
	c. Total	7,926.94	7,754.27	6,088.31	15,681.21	11,802.32	25,176.98
2	Expenditure						
	a. Cost of materials consumed	1,161.52	1,211.55	1,131.10	2,373.07	1,992.74	4,332.30
	b. Purchase of Stock-in-Trade	2,590.10	2,762.35	2,136.34	5,352.46	4,577.88	9,309.44
	c. Change in inventories of Finished Goods, work in progress and stock in trade	151.60	158.52	113.57	310.11	85.01	(79.71)
	d. Employees benefit expenses	593.44	542.41	449.28	1,135.85	856.20	1,877.87
	e. Depreciation	274.11	212.26	191.09	486.37	388.07	837.93
	f. Foreign Exchange Fluctuation Loss	178.76	83.49	140.19	262.25	131.18	259.95
	g. Research and Development Expenses	202.46	137.91	135.01	340.37	257.83	588.24
	h. Other Expenditure	783.08	782.82	704.81	1,565.90	1,421.18	2,991.99
	i. Total	5,935.07	5,891.31	5,001.39	11,826.38	9,710.09	20,118.01
3	Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)	1,991.87	1,862.96	1,086.92	3,854.83	2,092.23	5,058.97
4	Other Income	121.95	89.79	80.53	211.74	142.07	302.94
5	Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)	2,113.82	1,952.75	1,167.45	4,066.57	2,234.30	5,361.91
6	Finance cost	5.08	3.02	4.60	8.10	9.43	23.04
7	Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional items (5-6)	2,108.74	1,949.73	1,162.85	4,058.47	2,224.87	5,338.87
8	Exceptional items	-	-	-	-	-	-
9	Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)	2,108.74	1,949.73	1,162.85	4,058.47	2,224.87	5,338.87
10	Provision for Taxation	497.59	486.07	217.00	983.66	467.00	1,190.74
	Provision for Taxation - earlier years	-	-	-	-	(80.00)	(80.00)
	Deferred Tax Provision	0.85	55.36	30.00	56.21	60.00	115.48
	Mat Credit Entitlement	-	-	-	-	-	-
11	Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	1,610.30	1,408.30	915.85	3,018.60	1,777.87	4,112.65
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13	Net Profit(+)/Loss(-) for the period before minority interest (11-12)	1,610.30	1,408.30	915.85	3,018.60	1,777.87	4,112.65
14	Minority interest	0.16	0.12	2.30	0.28	3.79	8.96
15	Net Profit(+)/Loss(-) for the period after minority interest (13-14)	1,610.14	1,408.18	913.55	3,018.32	1,774.08	4,103.69
16	Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
17	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	7,435.01
18	Earnings/(Loss) Per Share (EPS) (Not annualised)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	10.66	9.32	6.05	19.98	11.74	27.16
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	10.66	9.32	6.05	19.98	11.74	27.16

Part II		Select information for the Quarter ended 31st DECEMBER 2015					
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		Three months ended			Six months ended		Year ended
		Dec 31, 2015	Sept 30, 2015	Dec 31, 2014	Dec 31, 2015	Dec 31, 2014	June 30, 2015
A	PARTICULARS OF SHARE HOLDING						
19	Public Shareholding						
	- Number of Shares	48,63,247	48,63,247	62,39,247	48,63,247	62,39,247	48,63,247
	- Percentage of Shareholding	32.19%	32.19%	41.29%	32.19%	41.29%	32.19%
20	Promoters and promoter group Shareholding						
	a) Pledged/encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	102,46,753	102,46,753	88,70,753	102,46,753	88,70,753	102,46,753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	67.81%	67.81%	58.71%	67.81%	58.71%	67.81%

B	Particulars	3 months ended 31-12-2015
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	172
	Disposed of during the quarter	171
	Remaining unresolved at the end of the quarter	1

STATEMENT OF ASSETS AND LIABILITIES	UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED 31ST DEC 2015		
	Unaudited Six Months ended		Audited Year ended
	31-12-2015 Rs. in Lakhs	31-12-2014 Rs. in Lakhs	30-06-2015 Rs. in Lakhs
Particulars			
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	1,511.00	1,511.00	1,511.00
Reserves and surplus	10,924.16	6,436.96	7,808.39
Total Shareholders' Funds	12,435.16	7,947.96	9,319.39
Minority Interest	26.95	21.50	26.66
Non current liabilities			
Long-term borrowings	57.46	154.32	87.99
Deferred tax liabilities (Net)	925.56	813.87	869.35
Long-term provisions	106.04	96.74	82.04
Total Non Current Liabilities	1,089.06	1,064.93	1,039.38
Current Liabilities			
Short-term borrowings	-	5.00	5.00
Trade Payables	3,976.45	3,186.84	4,170.16
Other current liabilities	6,868.06	8,609.53	7,211.40
Short-term provisions	336.92	572.68	1,110.64
Total Current Liabilities	11,181.44	12,374.05	12,497.20
TOTAL	24,732.61	21,408.43	22,882.63
ASSETS			
Non Current Assets			
Fixed assets			
(i) Tangible Assets	14,101.55	10,343.48	11,253.60
(ii) Intangible Assets	-	56.37	59.46
(iii) Capital work-in-progress	93.68	3,527.64	3,025.61
(iv) Intangible Assets under Development	35.59	9.01	36.94
Non-current investments	44.10	44.95	45.01
Long-term loans and advances	181.14	555.26	274.62
Total Non Current Assets	14,456.06	14,536.71	14,695.24
Current Assets			
Inventories	1,164.48	1,137.62	1,366.38
Trade receivables	642.63	1.22	566.46
Cash and cash equivalents	6,483.92	4,228.52	4,537.23
Short-term loans and advances	1,820.25	1,410.10	1,585.65
Other current assets	165.27	94.27	131.67
Total Current Assets	10,276.55	6,871.73	8,187.39
TOTAL	24,732.61	21,408.44	22,882.63

Notes :

- The Company operates in one segment only.
- The above consolidated unaudited financial results were considered and recommended by the Audit Committee of the Board and have been approved by the Board of Directors at its meeting held on 05.02.2016
- The statutory auditors have carried out a limited review of the results for the quarter and half year ended 31st December 2015
- The Board at its Meeting held on 5th February, 2016 declared an interim Dividend of Rs. 2.50 per share (25%) for the year 2015-16 and the same will be paid to those shareholders who hold shares in physical form and / or in electronic form and whose names appear in the Register of Members and / or Depositories respectively as at the closing hours on 16th February, 2016 (Record Date).
- The consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the company.
- Prior year / period figures are regrouped / rearranged wherever necessary.



Dr. Sridhar Ganesan
Managing Director



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

No. 43, (Old No. 22), Swathi Court, Flat No. C & D,
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

K. PARTHASARATHY
B.Com., FCA

Dr. C.N. GANGADAKAN
B.Com., FCA, MBIM (Lond.), Ph.d.

G. CHELLA KRISHNA
M.Com., FCA, PGPM

D. KALAIALAGAN
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., ACA

Limited Review on Unaudited Results

Review Report to

The Board of Directors,
Caplin Point Laboratories Limited
Chennai – 600017.

We have reviewed the accompanying statement of unaudited Consolidated financial results of CAPLIN POINT LABORATORIES LIMITED, Narbavi, No.3, Lakshmanan street, T.Nagar, Chennai – 600017, for the quarter ended 31st December, 2015 **except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.** This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Reg. No. 4915 S

B.RAMAKRISHNAN
Partner
Membership No. 201023
Place: Chennai
Date: 05/02/2016





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

No. 43, (Old No. 22), Swathi Court, Flat No. C & D,
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

S. NEELAKANTAN
B.Com., FCA

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

K. PARTHASARATHY
B.Com., FCA

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph d

G. CHELLA KRISHNA
M.Com., FCA, PGPM

D. KALAIALAGAN
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., ACA

Limited Review on Unaudited Results

Review Report to

The Board of Directors,
Caplin Point Laboratories Limited
Chennai - 600017.

We have reviewed the accompanying statement of unaudited Standalone financial results of CAPLIN POINT LABORATORIES LIMITED, Narbavi, No.3, Lakshmanan street, T.Nagar, Chennai – 600017, for the quarter ended 31st December, 2015 **except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.** This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Reg. No. 4915 S

B.RAMAKRISHNAN
Partner
Membership No. 201023
Place: Chennai
Date: 05/02/2016

